Receptor autologous tumor cells antigen of tumor. Medical search. Frequent questions

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. (marketbeat.com)
The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. (marketbeat.com)
Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. (marketbeat.com)
MAINZ, Germany I September 9, 2022 I BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") today presented positive follow-up data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and efficacy of the Company's novel CAR-T cell therapy candidate, BNT211, in patients with relapsed or refractory advanced solid tumors. (pipelinereview.com)
however, they may cause on-target off-tumor toxicity because of minimal expression of tumor-associated antigens (TAAs) on normal tissues, particularly in the context of treating solid tumors. (biomedcentral.com)
Hypoxia is a common hallmark of solid tumors because of the Warburg effect. (biomedcentral.com)
A previous study showed that oxygen-sensitive multichain CAR-T cells are responsive to hypoxia [ 7 ], while a simple single-chain hypoxia-inducible CAR-T cells (HiCAR-T cells) could respond to hypoxia within solid tumors is elusive. (biomedcentral.com)
Solid tumors, autoimmune diseases, graft versus host disease (GvHD), genetic diseases and neurodegenerative diseases are investigated using many types of autologous and allogeneic cells with rapidly evolving cell engineering and editing approaches. (bdbiosciences.com)
We're one of the few places looking at natural killer cells for solid tumors as well. (urotoday.review)
2019-004323-20 ) that aims to evaluate the safety and preliminary efficacy in heavily pretreated patients with relapsed or refractory advanced solid tumors. (biontech.de)
With the PRIME status and support by the EMA, we aim to expedite the further development of the BNT211 program to bring a novel therapeutic option for patients with life-threatening testicular cancer, and thus to extend the successes of CAR-T therapy also to hard-to-treat solid tumors. (biontech.de)
CARLSBAD, Calif.--(BUSINESS WIRE)-- Thermo Fisher Scientific , the world leader in serving science, and Arsenal Biosciences , Inc. (ArsenalBio), a clinical-stage cell therapy company engineering advanced chimeric antigen receptor (CAR)-T cell therapies for solid tumors, today announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments. (stevenagecatalyst.com)
By collaborating with ArsenalBio as they pioneer a new approach to treat solid tumors using engineered T cell therapies, we're helping bring more options to those who are most in need of innovative treatments," said Betty Woo, vice president of cell, gene and advanced therapies, Thermo Fisher. (stevenagecatalyst.com)
Research on a heart medication for childhood cancer survivors and new immunotherapies for blood and solid tumors will be presented. (wkrn.com)
Whether it's working on our own immunotherapy trials for solid tumors, or partnering with companies to find novel medicines, City of Hope is committed to transforming cancer care for our patients and beyond. (wkrn.com)
However, targeting solid tumors is more challenging than targeting B-cell malignancies with CAR-T cells because of the histopathological structure features, specific antigens shortage and strong immunosuppressive environment of solid tumors. (ijbs.com)
Optimization of the design of CAR vectors, exploration of new targets, addition of safe switches and combination with other treatments bring new vitality to the CAR-T cell based immunotherapy against solid tumors. (ijbs.com)
In this review, we focus on the major obstacles limiting the application of CAR-T cell therapy toward solid tumors and summarize the measures to refine this new cancer therapeutic modality. (ijbs.com)
Nevertheless, targeting solid tumors is more challenging than targeting hematological malignancies because of tumor histopathological characteristics, shortage of specific antigens and local strong immunosuppressive microenvironment [ 4 ]. (ijbs.com)
And much work remains to be done to improve the efficacy of CAR-T cell therapy for solid tumors. (ijbs.com)
It may be achieved, at least partially, by more extensive basic studies investigating the spatiotemporal dynamics of T cell activation by CARs and unraveling the connection between T cell migration in solid tumors and the effectiveness in eradication of solid tumors and metastases [ 5 ]. (ijbs.com)
In this review, we discuss the current status and major obstacles for the treatment of solid tumors with CAR-T cells, thus provide some potential measures to refine this novel therapeutic modality. (ijbs.com)

Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy. (elifesciences.org)
T cell-based immunotherapy, such as immune checkpoint blockade or adoptive T cell transfer, is limited by the ability of T cells to detect major histocompatibility complex (MHC)-presented antigen by tumor cells. (elifesciences.org)
Natural killer (NK) cell-based immunotherapy may overcome genetic mechanisms of resistance to T cell-based immunotherapy through antigen- and MHC-independent recognition of malignant cells. (elifesciences.org)
Thus, addressing the presence of immunosuppressive myeloid cell populations in the periphery and tumor microenvironment of patients with cancer is likely to be required for effective NK cell-based immunotherapy. (elifesciences.org)
Immunotherapy is emerging as a new form to treat cancer by harnessing the activity of cytotoxic CD8 + T lymphocytes (CTLs) that specifically recognize tumor-associated antigens. (lifeboat.com)
Overall, our study demonstrates the potential of the HiCAR for improving the safety of CAR-T cells to promote the clinical application of CAR-T immunotherapy. (biomedcentral.com)
Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
Nevertheless, ex vivo activation with cytokines can restore cytolytic activity of NK cells against GB, indicating that NK cells have potential for adoptive immunotherapy of GB if potent cytotoxicity can be maintained in vivo . (frontiersin.org)
Furthermore, similar to T cells, specific recognition and elimination of cancer cells by NK cells can be markedly enhanced through expression of chimeric antigen receptors (CARs), which provides an opportunity to generate NK-cell therapeutics of defined specificity for cancer immunotherapy. (frontiersin.org)
We then outline preclinical approaches that employ CAR-NK cells for GB immunotherapy, and give an overview on the ongoing clinical development of ErbB2 (HER2)-specific CAR-NK cells currently applied in a phase I clinical trial in glioblastoma patients. (frontiersin.org)
What is very challenging about any sort of immunotherapy, and in particular the checkpoint inhibitors, is that you need to get the treating product or the immune cells into the tumor microenvironment, which in the case of prostate cancer, happens to be the bone. (urologytimes.com)
Immunotherapy based on the adoptive transfer of ex vivo expanded and activated autologous tumor-reactive lymphocytes can mediate tumor regression in cancer patients. (unimedizin-mainz.de)
We successfully applied this strategy to the human TAAs p53, gp100 and MDM2-specific TCRs as promising antigens-driven immunotherapy for both melanoma and hematologic malignancies. (unimedizin-mainz.de)
This joint (Frankfurt/Mainz, Dresden, Essen, Heidelberg) translational immunotherapy project aims to combine NK cells as effector cells with universal epitope-specific CAR (UniCAR) with tunable activity. (unimedizin-mainz.de)
Well-differentiated neuroendocrine tumors are resistant to conventional immunotherapy with checkpoint inhibitors. (netrf.org)
Involving the direct use of whole cells or cellular material in patients, cell therapy is an umbrella term for many subdivisions of biological research, encompassing fields such as stem cell therapy, gene therapy and immunotherapy. (ddw-online.com)
Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
Background IGV-001 is a personalized, autologous cancer cell-based immunotherapy conceived to deliver a tumor-derived antigenic payload in the context of immunostimulatory signals to patients with glioblastoma (GBM). (jefferson.edu)
The use of immunomodulatory adjuvants, eg, vaccination or cytokine therapy, for in vivo T-cell activation may help overcome this metabolic quiescence and thus augment cellular immunotherapy-based cancer therapy. (johnshopkins.edu)
Collectively, the BsAb-armed T cell technology represents a simple, time-saving, and highly safe method to generate highly pure cancer-specific effector T cells, thereby providing an affordable T cell immunotherapy to patients. (biomedcentral.com)
Over the last Etretinate few years, immunotherapy has Etretinate demonstrated impressive efficacy for many tumors. (mindunwindart.com)
CAR-T cell therapy has achieved outstanding progresses in clinical observations, which makes it even more attractive in the development of cancer adoptive immunotherapy. (ijbs.com)

T-cell clones were stimulated every 10-14 days with irradiated allogeneic PBMC and phyto-hemagglutinin in IMDM with 5% human serum (HS), 5% FBS and 100 IU/mL IL-2 as previously described. (haematologica.org)

Immune stimulating antibody conjugates work by activating dendritic cells within the tumor, and are capable of being delivered systemically. (wikipedia.org)
The researcher, Stanford's Ed Engleman, has built on his research into dendritic cells - which are considered 'sentinels' of the immune system as they are responsible for inducing immune T-cell responses - to develop this Immune-Stimulating Antibody Conjugate (ISAC) technology, which was unveiled by exclusive licensee Bolt Biotherapeutics at the American Association for Cancer Research (AACR) Conference on Monday. (wikipedia.org)
What Bolt has come up with is to wake up dendritic cells within the (tumor) microenvironment, and we were able to do this in a targeted way," said David Dornan, senior VP of research, in an interview with Endpoints News ahead of the conference. (wikipedia.org)
Patient PBMCs are collected by leukapheresis followed by enrichment approaches to isolate T cells while removing other cells such as B cells, monocytes, neutrophils, dendritic cells and contaminating tumor cells. (bdbiosciences.com)
NK cells contribute to cancer immune surveillance not only by their direct natural cytotoxicity which is triggered rapidly upon stimulation through germline-encoded cell surface receptors, but also by modulating T-cell mediated antitumor immune responses through maintaining the quality of dendritic cells and enhancing the presentation of tumor antigens. (frontiersin.org)
Immunophenotyping confirmed that IGV-001 increases the percentage of dendritic cells, as well as effector, and effector memory T cells in BDC-draining lymph nodes. (jefferson.edu)
2.?Cancers vaccines Despite the fact that autologous dendritic cells (DCs) pulsed with antigen-undefined tumor cell lysate are also explored to take care of HCC (Palmer et al. (mindunwindart.com)

it recognizes a specific protein on the surface of malignant cells (eg, CD19 on B-cells). (medscape.com)
Kochenderfer et al described dramatic regression of the lymphoma after infusion of CAR T cells engineered to target CD19. (medscape.com)
In total, 3 CAR T-cell therapies are now on the market, all targeting the CD19 antigen. (ajmc.com)
We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. (nih.gov)
A specific immune response was detected in the bone marrow, accompanied by loss of normal B cells and leukemia cells that express CD19. (nih.gov)
CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
In the last 2 years treatment with autologous CAR T cells directed against the CD19 antigen has been introduced in therapy of autoimmune disease. (bvsalud.org)
CD19 CAR T cells induced a rapid and sustained depletion of circulating B cells, as well as in a complete clinical and serological remission of refractory systemic lupus erythematosus and dermatomyositis. (bvsalud.org)
The emerging therapeutic approach of CAR-T cell therapy has sparked great interests, extensive studies in preclinical and clinical trials have revealed encouraging therapeutic efficacy in treating a variety of cancers, particularly in treating B-cell hematologic malignancies with CD19 CAR-T cells [ 3 ]. (ijbs.com)
ImmPACT Bio has opened a facility in LA to support IMPT-314, a CD19/CD20 bispecific CAR-T candidate for B-cell mediated malignancies and autoimmune diseases. (bioprocessintl.com)
The chimeric antigen receptor (CAR) T-cell therapy aims to address patients who relapse with tumors that have lost CD19 expression. (bioprocessintl.com)
CD19 and CD20 expression is only on B cells and B-cell tumors, and therefore adding specificity for CD20 and CD19 does not have added toxicities. (bioprocessintl.com)
The two binding domains are in a compact structure that enables high expression and are, like the CD19 CARs, connected to signaling motifs that activate T-cell tumor killing. (bioprocessintl.com)
From the leukapheresis material collected from the patient, enriched CD62L+ cells are activated, then genetically modified by lentiviral vector transduction to integrate the CD19/CD20 CAR plasmid into the T cell genome. (bioprocessintl.com)

Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. (nature.com)
Interestingly, vaccination-induced Trm cells strongly suppress the growth of melanoma, independently of circulating CD8 T cells, and were able to infiltrate melanoma tumors. (lifeboat.com)
Transfusion of autologous tumor-specific CTLs 1-4 and blockade of T cell inhibitory receptors 5-7 have demonstrated to elicit durable clinical benefit in a significant proportion of patients with melanoma, leukemia, lymphoma and other cancers, who failed to respond to conventional treatments. (lifeboat.com)
3 Autologous lymphocytes genetically modified with the TCR for MART-1/Melan-A have been adoptively transferred to patients with advanced melanoma. (haematologica.org)
In contrast to other cancers such as adenocarcinomas of the lung or melanoma, primary brain tumors like GB and low grade gliomas (LGG) are known as rather immunologically "cold" tumors, typically with low numbers of tumor-infiltrating lymphocytes (TILs) ( 4 ), and the mere amount of TILs is not associated with patient survival ( 5 ). (frontiersin.org)
The therapeutic candidate is administered as an infusion and constitutes autologous T cells genetically engineered to express T-cell receptors (TCR) targeting cancer cells expressing melanoma associated antigen 3 and 6 and is developed based on engineered autologous cell therapy (eACT) platform.It was under development for relapsed and refractory multiple myeloma. (globaldata.com)
Focusing on advanced melanoma, we will investigate the antitumor activity of UniCAR NK cells in clinically relevant models. (unimedizin-mainz.de)
Recombinant targeting modules will be based on antibodies and soluble single-chain fragments of TCR specific for melanoma antigens. (unimedizin-mainz.de)
Adoptive cell therapy using engineered T-cell receptors (TCRs) targeting cancer-testis antigens, such as Melanoma-associated antigen 3 (MAGE-A3), is a potential approach for the treatment of NSCLC. (thno.org)
From 2004 to 2006, more than 40 patients were treated with autologous gene-modified lymphocytes expressing a melanoma antigen-specific TCR at the National Cancer Institute. (johnshopkins.edu)
Here, we develop a syngeneic melanoma mouse model of LN metastasis to investigate how tumors spread to LNs and whether LN colonization influences metastasis to distant tissues. (stanford.edu)

Here, we describe the pre-clinical in vitro and in vivo study of irradiated haNK cells engineered to express a second-generation chimeric antigen receptor (CAR) targeting programmed death-ligand 1 (PD-L1). (elifesciences.org)
Autologous TILs were expanded ex vivo from minced tumors cultured with interleukin-2. (nature.com)
Vaccination-induced Trm cells were largely resistant to in vivo intravascular staining and antibody-dependent depletion. (lifeboat.com)
Autoimmune side effects, however, remain a risk, emphasizing the relevance of a suicide mechanism allowing in vivo elimination of infused T cells. (haematologica.org)
Adverse side effects, however, may occur and lead to severe autoimmunity or graft-versus-host disease (GvHD), emphasizing the relevance of a suicide mechanism that allows efficient in vivo elimination of infused T cells. (haematologica.org)
Transfer of HSV-tk to DLI preserves the beneficial anti-tumor effect and allows in vivo elimination of donor T cells if severe GvHD occurs. (haematologica.org)
A low dose (approximately 1.5×10(5) cells per kilogram of body weight) of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. (nih.gov)
HiCAR-T cells showed enhanced cytotoxicity against tumor cells under hypoxia compared to normoxia in vitro and antitumor efficacy comparable to that of conventional CAR-T cells in vivo. (biomedcentral.com)
T cells are modified ex vivo by transduction with viral vectors containing CAR or other modifications of interest. (bdbiosciences.com)
Here, we discuss effects of the GB tumor microenvironment on NK-cell functionality, summarize early treatment attempts with ex vivo activated NK cells, and describe relevant CAR target antigens validated with CAR-T cells. (frontiersin.org)
Area A will delineate the diagnostic potential of TSPO imaging by means of positron emission tomography (PET) in brain tumors in vivo and will enable the complementary characterization of brain tissue in vitro to delineate the neurobiological characteristics underlying TSPO PET labeling in the human brain. (uni-regensburg.de)
Similar to the experience of others, we've always been faced with the fact that we used to use retroviral vectors to generate the final CAR product and that there are challenges to in how to maximize the in vivo efficacy of the CAR T cell. (urologytimes.com)
The ability of the BiTE-like molecule to efficiently activate T cells against NETs in vivo will be tested on 6-8-week-old NOD/Shi-scid/IL-2Rγnull mice with SSTR+ NET subcutaneous xenografts. (netrf.org)
The CAR-T cell manufacturing platform is based on the ex vivo genetic engineering of a patient's T cells to express CAR, followed by the reinfusion of the T cells into the patient. (biomedcentral.com)

Many patients are refractory to checkpoint inhibitors because there are a number of immunosuppressive factors present in their tumor microenvironment, and so researchers have been trying to harness different molecules to stimulate the immune system, one of which are toll-like receptor (TLR) agonists - specialized proteins that initiate an immune response to foreign pathogens or, in this case, cancer cells. (wikipedia.org)
The fourth generation of CAR-T design attempts to deliver cytokines to modulate the tumor microenvironment either by activating host effector T cells or hampering host suppressors and reinforcing memory T cells. (bdbiosciences.com)
While GB tumors are frequently infiltrated by natural killer (NK) cells, these are actively suppressed by the GB cells and the GB tumor microenvironment. (frontiersin.org)
Nevertheless, the composition of the immunologic tumor microenvironment undergoes changes upon radiotherapy, chemotherapy, or even after anti-angiogenic therapy ( 6 ). (frontiersin.org)
A preparative regimen is needed to remove any inhibitory immune cells, ie, regulatory T cells (Tregs) that may contribute to a hostile tumor microenvironment, thereby providing an intratumoral milieu that blocks immune cell penetration. (urologytimes.com)
Our goal is to develop a BiTE-like molecule that targets SSTR-expressing NET cells and is potentially more concordant with the characteristics of the NET immune microenvironment. (netrf.org)

CD20-transduced T cells with and without co-transferred T-cell receptor were efficiently eliminated by complement dependent cytotoxicity induced by therapeutic anti-CD20 antibody rituximab. (haematologica.org)
We identified the HLA-A2 restricted T cell epitopes from MAGE-A3 that could effectively induce the activation and cytotoxicity of CD8+ T cells using artificial APC in vitro . (thno.org)
LN metastases resist T cell-mediated cytotoxicity, induce antigen-specific regulatory T cells, and generate tumor-specific immune tolerance that subsequently facilitates distant tumor colonization. (stanford.edu)
Modification with chimeric antigen receptors (CARs) endows T cells with tumor specific cytotoxicity and thus induce anti-tumor immunity against malignancies. (ijbs.com)

In approved products, a patient's own T lymphocytes are collected by apheresis and transduced with a gene that encodes for a CAR to direct the T cells against cancer cells. (medscape.com)
Although human CD20 has previously been described as functional selection marker and suicide gene after retroviral transfer to T lymphocytes, 9 , 10 the specificities of these T cells were unknown, and therefore a potential effect of CD20 on antigen-specific T-cell functions could not be investigated. (haematologica.org)
This research project will test whether the somatostatin receptor (SSTR)- CD3 bispecific T- cell engager (BiTE)-like molecules that we developed, can efficiently activate the tumor infiltrating lymphocytes (TILs) against the SSTR-expressing NET cells. (netrf.org)
Other agents are necessary to activate tumor infiltrating lymphocytes (TILs). (netrf.org)
Recent studies have shown that soluble factors elaborated by human T lymphocytes enhance erythroid burst formation by human peripheral blood null cells. (shengsci.com)
Retroviral transduction of tumor antigen-specific T-cell receptor (TCR) genes into lymphocytes redirects T cells to lyse tumors. (johnshopkins.edu)

Kite Pharma, a subsidiary of Gilead, received an accelerated approval in July 2020 for brexucabtagene autoleucel (Tecartus) for adults with relapsed or refractory mantle cell lymphoma. (ajmc.com)
We describe a Phase I dose escalation study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) therapy for relapsed or refractory (r/r) T-cell leukemia and lymphoma. (march.bio)

These experimental cytokine-producing CAR-Ts, called T cells redirected for universal cytokine killing (TRUCKs), can deliver a variety of cytokines, such as IL-12, IL-15, IL-18 or IL-21. (bdbiosciences.com)
NK cells can enhance T-cell activation without production of cytokines linked to adverse reactions. (unimedizin-mainz.de)
Cytotoxins (perforin and granzyme) and cytokines (TNF-α and IFN-γ) were dramatically released from the BsAb-armed T cells after engaging cancer cells, resulting in a remarkable anti-cancer efficacy. (biomedcentral.com)
Nonspecific immunotherapies, including cytokines (such as IFN, IL-2, TGF- inhibitors, and so forth) and cytokines-induced killer cells (CIK) (Lee et al. (mindunwindart.com)
After a few days of expansion in presence of cytokines, the cells are harvested, washed, formulated and filled, then cryopreserved for storage in liquid nitrogen until quality release testing is completed. (bioprocessintl.com)

Mechanically, immune stimulating antibody conjugates required tumor antigen recognition, FcγR-dependent phagocytosis and TLR-mediated activation to drive tumor killing by myeloid cells and subsequent T-cell-mediated antitumor immunity. (wikipedia.org)
Donor T cells may also induce GvHD due to recognition of allo-antigens on non-malignant tissues of the patient. (haematologica.org)
CAR-expression on T or NK cells allows them to specifically target cancer cells via recognition of tumor associated antigens. (nature.com)
Furthermore, the so-called adapter CARs have been developed by splitting antigen recognition and CAR-immune cell activation. (nature.com)
After TCR identification, we generated HLA-A*02:01/peptide restricted TCR transgenic T cells by retroviral transduction and tested T cell expansion rates as well as A*02:01/peptide recognition and ES killing in ELISpot and xCELLigence assays. (oncotarget.com)
TCR transgenic T cells demonstrated HLA-A*02:01/ADRB3 295 mediated ES recognition and killing in ELISpot and xCELLigence assays. (oncotarget.com)
Recent years have seen the emergence of many strategies to spatiotemporally control CAR-T cell activities through regulating antigen recognition [ 5 , 6 ], but the application of tumor environmental signals (e.g., acidosis and hypoxia) may represent an attractive strategy to control CAR-T cells. (biomedcentral.com)
We aimed to develop a CAR design that require both antigen recognition and hypoxia sensing to generate optimal T cell activity, thereby reducing on-target off-tumor toxicity. (biomedcentral.com)
Importantly, T cells artificially expressing the MAGE-A3-Mp4 specific TCRs exhibited strong MAGE-A3+ tumor cell recognition and killing effect. (thno.org)
Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. (shengsci.com)

Herpes simplex virus thymidine kinase (HSV-tk) is a well-established suicide gene that has been successfully used to control GvHD following donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation. (haematologica.org)
4 In addition, TCRs for minor histocompatibility antigens, including HA-1 and HA-2, have been transferred to donor-derived virus-specific T cells to treat patients with hematologic malignancies after allogeneic stem cell transplantation. (haematologica.org)
they include hematopoietic stem cells and adult and embryonic stem cells. (ajmc.com)
it is a non-viral transposon system (piggyBac®) that results in a CAR T product comprised of a high percentage of T stem cell memory cells. (urologytimes.com)
Genes are inserted encoding a PSMA-targeted Centyrin CAR with an iCasp9-based safely switch and DHFR to purify CAR T Cells.These T stem cell memory cells have bone marrow homing capability that may be particularly relevant to bone tropic tumors, such as prostate cancer. (urologytimes.com)
Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
Between February 1986 and March 1990, 56 patients with relapsed Hodgkin's disease treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) received an autologous peripheral stem cell transplantation (PSCT) rather than an autologous bone marrow transplantation (ABMT) because each patient had a marrow abnormality, either hypocellularity or tumor involvement. (shengsci.com)
Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial Lancet Oncology 21 (10): 1317-1330,2020. (pennmedicine.org)
Translational Candidate s15.BsAb.BCMA-CAR NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with multiple myeloma Mechanism of Action s15.BsAb.BCMA-CAR NK cells are umbilical cord blood-derived CD34+ hematopoietic stem cells that are engineered to include two components of the BCMA-CAR and the anti-NKG2D-anti-GPRC5D BsAb. (ca.gov)
Translational Candidate stem cell-based off-the-shelf CAR-iNKT cells Area of Impact multiple myeloma (MM) Mechanism of Action The proposed therapeutic candidate can directly kill MM tumor cells. (ca.gov)
Translational Candidate Lenti/iNKT-sr39TK Modified Autologous Human CD34+ Hematopoietic Stem Cells (HSCs) Area of Impact The targeted area of impact for the candidate is cancer therapy, in particular cancers that are lacking existing effective treatments. (ca.gov)
In this ongoing Phase II multicenter study, 55 heavily pretreated patients with relapsed/refractory DLBCL, including almost 50% without a response to autologous stem cell transplantation (ASCT), were treated with fludarabine/cyclophosphamide lymphodepletion, followed by a dose of JCAR17. (medpagetoday.com)
1 line of systemic therapy in case of participants ineligible for high-dose chemotherapy and autologous Hematopoietic stem cell transplantation (HSCT). (who.int)
Results showed that adding quizartinib to standard chemotherapy with or without allogeneic hematopoietic stem cell transplantation, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival. (medscape.com)
Motixafortide is indicated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. (medscape.com)
SDF-1α and CXCR4 play a role in trafficking and homing of human hematopoietic stem cells to the marrow compartment. (medscape.com)
With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)

The UniCAR is only activated upon cross-linking through a soluble tumor-targeting module carrying the UniCAR binding epitope, thereby achieving highest tumor specificity. (unimedizin-mainz.de)
T cells and TCR will be obtained from blood and tumor tissue and tested for neoantigen specificity and tumor reactivity. (unimedizin-mainz.de)
However, most effector T cells generated using these established cultivation methods lack cancer specificity [ 8 ]. (biomedcentral.com)

Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
Poseida Therapeutics is testing the safety of a gene modified cell therapy to treat multiple myeloma, the abnormal growth of malignant plasma cells of the immune system. (ca.gov)
Research Objective We will use integrated gene editing techniques to develop a new CAR-T cell therapy for multiple myeloma treatment Impact Develop an improved CAR-T cell therapy for patients with refractory multiple myeloma and a new manufacturing strategy that circumvents the costs and inefficiencies of viral production. (ca.gov)
Translational Candidate A single-chain bispecific chimeric antigen receptor (CAR) targeting BCMA and CS1 will be used to in autologous T-cell therapy for multiple myeloma. (ca.gov)
Area of Impact Translational candidate will enable treatment of patients with heterogeneous or BCMA- multiple myeloma and prevent cancer relapse due to antigen loss. (ca.gov)
Elranatamab is an antibody that binds to both CD3 on T-cells and B-cell maturation antigen (BCMA), which are expressed on the surface of multiple myeloma cells. (medscape.com)
Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort. (cdc.gov)
Smoldering) multiple myeloma: mismatch between tumor load estimated from bone marrow biopsy at iliac crest and tumor load shown by MRI. (cdc.gov)

Autologous as well as allogeneic CD8 + T cells transduced with tumor antigen specific T cell receptors (TCR) may cause significant tumor lysis upon adoptive transfer. (oncotarget.com)
The binding of specific T cell receptors (TCR) to major histocompatibility complex (MHC)/antigen complexes on cancer cells induces the TCR/CD3-mediated signal transduction pathway and stimulates the release of specific toxins (perforin and granzyme) for cancer elimination [ 6 , 7 ]. (biomedcentral.com)

This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with autologous CD4 and CD8 T cells lentivirally transduced to express a HER2-specific chimeric antigen receptor (CAR) and EGFRt, delivered by an indwelling catheter in the tumor resection cavity or ventricular system in children and young adults with recurrent or refractory HER2-positive CNS tumors. (fredhutch.org)
A child or young adult with a refractory or recurrent CNS tumor will have their tumor tested for HER2 expression by immunohistochemistry (IHC) at their home institution or at Seattle Children's Hospital. (fredhutch.org)
[ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
Our preliminary experience with CARTs has been primarily against a variety of relapsed, refractory B-cell malignancies including ALL, CLL, and NHL. (medpagetoday.com)
Most recently, data for the efficacy of the JCAR17 platform for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the most common lymphoma in the United States, were presented by Dr. Jeremy Abramson and his colleagues at the 2017 International Conference on Malignant Lymphoma. (medpagetoday.com)
Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions and possibly cure patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with poor prognosis and no standard therapeutic options. (medpagetoday.com)

T cell-targeted immunomodulators such as monoclonal antibodies against PD-1 or CTLA4 may be used in combination with CAR-T cells in clinical trials. (bdbiosciences.com)
B-cell-depleting monoclonal antibodies, such as rituximab, have poor therapeutic efficacy in autoimmune diseases, mainly due to the persistence of autoreactive B cells in lymphatic organs and inflamed tissues. (bvsalud.org)

TSPO is overexpressed in primary brain tumors and has been shown to correlate with the malignancy of the tumor cells. (uni-regensburg.de)

This GINAKIT2 phase 1 clinical trial, the first to use of genetically engineered NKT cells in humans, will evaluate the anti-tumor activity of GD2 specific CAR and interleukin-15 expressing autologous NKT cells. (texaschildrens.org)
In this case, CARs include a part specific for the GD2 molecule, which is present at high levels in NB tumors and has already led to promising results in clinical trials of GD2-targeted T cells in NB patients. (texaschildrens.org)
Several types of adoptive cell transfer are under investigation, but CAR T-cell therapy is the first to enter clinical practice. (medscape.com)
Vaccination strategies eliciting CTL responses specific for tumor-specific and self-antigens have shown promising results in recent clinical trials. (lifeboat.com)
Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. (nature.com)
In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany. (nature.com)
So far, it is not known which tumor features are reflected by the different imaging modalities and whether this has an impact on the clinical outcome and prognosis of patients. (uni-regensburg.de)
Promising combinations of UniCAR NK cells and distinct targeting molecules will be identified for subsequent translation into a phase clinical study. (unimedizin-mainz.de)
Specifically, he is interested in the utilization of compounds with novel mechanisms of action in clinical trials for the treatment of these tumors. (mdanderson.org)
March Biosciences, a clinical-stage cell therapy company, proudly welcomes Peter Olagunju to its Board of Directors. (march.bio)
ArsenalBio recently advanced its lead product candidate into clinical manufacturing of its autologous integrated circuit T cell (ICT) therapy for platinum-resistant ovarian cancer. (stevenagecatalyst.com)
Thermo Fisher began its collaboration with ArsenalBio in 2020 to help ArsenalBio overcome challenges associated with cell therapy manufacturing by working together to support development of a clinical-scale gene editing process. (stevenagecatalyst.com)
Thermo Fisher's CTS portfolio of products are cGMP manufactured, designed to meet applicable cell therapy standards, and include traceability and regulatory documentation to help customers transition from research to clinical production. (stevenagecatalyst.com)
Cancer-specific adoptive T cell therapy has achieved successful milestones in multiple clinical treatments. (biomedcentral.com)
Recent years, we have witnessed significant progresses in both basic and clinical studies regarding novel therapeutic strategies with genetically engineered T cells. (ijbs.com)

The adoptive transfer of T cells engineered to target tumour cells via chimeric antigen receptors (CARs) has emerged as an effective treatment modality in B-cell malignancies. (bvsalud.org)

Potential effects of forced CD20 expression on T-cell function were investigated by comparing CD20- and mock-transduced cytomegalovirus (CMV) specific T cells for cytolysis, cytokine release and proliferation. (haematologica.org)
Lipid signaling pathways regulate a multitude of cellular behaviors in humans including cell proliferation, death, migration, and many other attributes. (selectbiosciences.com)
The anti-CD3 moiety of the BsAb bound to the T cell surface and stimulated the differentiation and proliferation of T cells in PBMCs. (biomedcentral.com)
Quizartinib and its active metabolite (AC886) inhibit FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. (medscape.com)
Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
Лімфома Ходжкіна Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)

Receptors recognizing and then attacking normal cells is what can cause toxicity. (ajmc.com)
SSTR-specific tumor toxicity will be assessed by coculturing T cells isolated from peripheral blood of healthy donors with SSTR-expressing NET cells by RTCA. (netrf.org)
Notably, the BsAb-armed T cells did not cause obvious cytokine release syndrome or tissue toxicity in SCID mice bearing human tumors. (biomedcentral.com)
Meanwhile, the on-target/off-tumor toxicity caused by relative expression of target on normal tissues is another issue that should be reckoned. (ijbs.com)
Furthermore, the on-target/off-tumor toxicity can pose significant risks. (ijbs.com)

In preclinical testing, the company says that these immune-stimulating antibody conjugates eliminated tumors. (wikipedia.org)
3 4 Preclinical studies of LB2102, an autologous DLL3-directed CAR-T cell, have demonstrated DLL3-specific antitumor effects with a low risk of on-target/off-tumor toxicities and off-target/off-tumor toxicities. (bmj.com)
In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity. (march.bio)
These preclinical design details incorporated into well-defined JCAR17 constructs have been purported to result in better expansion, improved efficacy against tumors, and more predictable and consistent pharmacodynamics. (medpagetoday.com)

The intracellular domains ensure intracellular signaling necessary to activate the effector functions of the CAR T cell. (medscape.com)
Here, we demonstrate that NK cells (haNKs) engineered to express a PD-L1 chimeric antigen receptor (CAR) haNKs killed a panel of human and murine head and neck cancer cells at low effector-to-target ratios in a PD-L1-dependent fashion. (elifesciences.org)
Accordingly, long-lived memory precursor effector T cells and antigen-specific T cells were increased by PD-1 blockade in intracranial lesions. (bvsalud.org)
11 They have been typically classified in two subsets: effector-memory (Tem) and central-memory (Tcm) CD8 + T cells. (lifeboat.com)
Statistical and machine-learning based analyses demonstrated that the MAGE-A3-Mp4 epitope-specific CD8+ T cell clones were mostly in effector and proliferating state. (thno.org)
Consistent with these observations, preventative IGV-001 limited tumor progression and extended overall survival in mice intracranially challenged with GL261 cells, a benefit that was associated with an increase in tumor-specific T cells with effector features. (jefferson.edu)
While these cells show some features of exhaustion, they maintain high proliferative potential and are able to both self-renew and replenish populations of exhausted effector T cells that mediate control in chronic viral infections and tumors. (acir.org)
Decreasing the dose of the virus increased IFNγ production by TP cells, suggesting that higher antigen loads led to the generation of TP cells with repressed effector functions. (acir.org)
Using multidimensional scaling analysis to cluster cells based on features of T cell exhaustion over time revealed that early (day 5) TP cells in chronic infection resembled established signatures for precursors of exhausted (day 21) T cells, while early TE cells from mice with chronic infection resembled the polyfunctional effector cells that were prominent in acute infection. (acir.org)

An immune stimulating antibody conjugate comprising a TLR7/TLR8 dual agonist conjugated to antibodies targeting at human epidermal growth factor receptor 2(HER2) has been developed. (wikipedia.org)

Cancer immunotherapies aim to support or boost the patient's immune system to enable the effective clearance of cancer cells. (nature.com)
Development of a novel anti-SSTR bispecific T-cell engager (BiTE)-like molecule for the treatment of neuroendocrine tumors (NETs), focusing on developing a new type of t-cell engager molecule that may be used in the development of immunotherapies to improve the treatment of SSTR-expressing NETs. (netrf.org)
Broadly, immunotherapies can be Etretinate divided into antigen-undefined (nonspecific) and antigen-defined (specific) immunotherapies. (mindunwindart.com)
On leading of particular immunotherapies, cancers vaccines, T cell receptor (TCR) and chimeric antigen receptor (CAR) geneengineered T cells (TCRTs and CARTs) have already been actively examined for HCC. (mindunwindart.com)

The genetically modified autologous T cells are expanded in vitro at a production facility and then reinfused into the patient. (medscape.com)
T-cell receptor (TCR) gene transfer is an attractive strategy for rapid in vitro generation of high numbers of antigen specific T cells. (haematologica.org)
In this study, we comprehensively screened HLA-A2 restricted MAGE-A3 tumor epitopes and characterized the corresponding TCRs using in vitro artificial antigen presentation cells (APC) system, single-cell transcriptome and TCR V(D)J sequencing, and machine-learning. (thno.org)
Described here are some of the general requirements of in vitro test methods for skin sensitization, and progress that has been made in developing suitable approaches with particular emphasis on the utility of dendritic cell culture systems. (cdc.gov)

The results demonstrated encouraging signs of anti-tumor activity and the safety profile remained manageable for the two tested dose levels. (pipelinereview.com)
The results demonstrated that treatment with CLDN6 CAR-T alone or in combination with CARVac was well tolerated and showed encouraging signs of anti-tumor activity in testicular cancer patients at the first evaluated dose levels. (biontech.de)

Chimeric antigen receptors (CAR)-engineered T cells have demonstrated remarkable efficacy in patients with B-cell malignancies. (unimedizin-mainz.de)

Resident memory CD8 + T (Trm) cells stably reside in non-lymphoid tissues and mediate superior innate and adaptive immunity against pathogens. (lifeboat.com)
However, the specific contribution of Trm cells to anti-tumor immunity is incompletely understood. (lifeboat.com)
8-10 Long-lasting protective immunity relies on the efficient establishment of long-lived memory CD8 + T cells, which have the potential to eradicate primary and disseminated tumors. (lifeboat.com)
The aim of adoptive T-cell therapy of cancer is to selectively confer immunity against tumor cells. (haematologica.org)
T-cell therapies based on chimeric antigen receptor (CAR) T-cells are widely employed for this purpose, as they have the capacity to proliferate within the patient after infusion and offer sustained functional immunity. (ddw-online.com)
Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity. (stanford.edu)
When loaded with immune complexes (IC), consisting of tumor antigens bound to antitumor antibody, BMDC induce powerful antitumor immunity in mice. (stanford.edu)

Cell therapy with autologous TILs is generally safe and clinically active and may constitute a new treatment strategy in metastatic lung cancer. (nature.com)

Fig. 5: Change in phenotype and genotype of peripheral T cells after TIL infusion. (nature.com)
Prior to infusion of the CAR-modified immune cells, lymphodepletion is performed in most therapeutic settings to allow efficient cell engraftment [ 10 ]. (nature.com)
All 22 patients showed robust, dose-dependent CAR-T cell expansion after infusion with cell frequencies close to 10 9 total counts in dose level 2. (pipelinereview.com)
Quality control testing is essential to ensure the CAR-T cell product meets established specifications for manufacturing release and patient infusion. (bdbiosciences.com)
Patients receive lympho-depleting chemotherapy of standard regimen fludarabine and cyclophosphamide, followed 72 hours later by the infusion of the autologous CAR T cells. (urologytimes.com)
This specific construct consists of equal quantities of CD4+/CD8+ CARTs which are transduced separately after apheresis and directed against CD-19 on tumor cells subsequently in a 1:1 infusion. (medpagetoday.com)

1 , 2 The anti-tumor effect of DLI is mediated by donor T cells recognizing allo-antigens on the malignant cells of the recipient. (haematologica.org)
Normally, potentially malignant cells are continuously eliminated by the immune system, but cancer cells can accumulate certain mutations, which allow them to escape these mechanisms [ 2 ]. (nature.com)
CAR-modified immune cells are expanded until sufficient cell numbers are attained and are adoptively transferred into the patient to fight malignant cells. (nature.com)

With some patients being resistant to checkpoint inhibitors, immune stimulating antibody conjugates may be able to harness an immune response generated through the stimulation of toll-like receptors. (wikipedia.org)
CAR-T are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) that, elicit a non-MHC restricted immune response against tumor associated antigens (TAA). (netrf.org)

In murine models, intracranial rechallenged tumors after initial rejection by PD-1 blockade were suppressed. (bvsalud.org)
Although immune checkpoint blockade (ICB) reinvigorates anti-tumor immune responses by disrupting co-inhibitory T-cell signaling, relapse frequently occurs after ICB treatment and acquired resistance often emergence after initial response [ 4 ]. (thno.org)
2010). Defense checkpoint blockade (PD-1 and PD-L1 inhibitors) to recovery T cell function provides generated amazing (~20%) general response price in treating past due stage HCC sufferers (Hato et al. (mindunwindart.com)

Development of a Novel Anti-SSTR Bispecific T-cell Engager (BiTE)-like Molecule for the Treatment of Neuroendocrine Tumors (NETs). (netrf.org)
In this study, we developed a non-genetic engineering technology for rapidly manufacturing a large amount of cancer-specific T cells by utilizing a unique anti-cancer/anti-CD3 bispecific antibody (BsAb) to directly culture human peripheral blood mononuclear cells (PBMCs). (biomedcentral.com)
It is a bispecific humanized monoclonal antibody against CD3, a T-cell surface antigen, and GPRC5D (human G-protein coupled receptor family C group 5 member D), a tumor-associated antigen with potential antineoplastic activity. (medscape.com)

The company's therapies consist of a tumor-targeting antibody that homes in on tumors and is paired with an immune stimulant that turns cold tumors into hot ones. (wikipedia.org)
Although only a handful of cell and gene therapies are on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies, and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year. (ajmc.com)
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. (nature.com)
Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. (nature.com)
Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
Investigational cell therapies are addressing a wide range of hematological malignancies. (bdbiosciences.com)
Alicia Morgans interviews Nick Zorko, who shares his excitement about his team's work on natural killer (NK) cell therapies, specifically focusing on engineered NK cells to target the tumor marker B7-H3. (urotoday.review)
Dr. Zorko believes that NK cell therapies will be safer, more accessible, and possibly suitable for outpatient settings, which is particularly beneficial for prostate cancer patients who are often older and may have multiple comorbidities. (urotoday.review)
So the University of Minnesota is very focused on natural killer cell therapies. (urotoday.review)
As such, preserving the integrity of sensitive samples is a daily challenge for cell culture laboratories in their search for innovative new therapies. (ddw-online.com)
For research purposes, autologous cell therapies are often favoured because they do not require immunological matching and are personalised to the patient. (ddw-online.com)
One area in which autologous therapies have shown particular potential is in the treatment of cancer. (ddw-online.com)
Immuno-oncology therapies typically use genetically modified T-cells to combat and kill cancerous tissue by identifying the cancer cells as a foreign body in need of attack. (ddw-online.com)
These innovative therapies rely on the use of techniques and technologies that minimise the risk of contamination and achieve the strictly-controlled, secure environment necessary for growing healthy, viable cells. (ddw-online.com)
While cell therapies show great promise in bringing innovative and much needed treatments to patients, there are a number of key issues currently limiting their broader adoption. (ddw-online.com)
Safety concerns over the administration of live cells to patients, uncertainties over the way in which these therapies should be regulated, unknown downstream effects and the need for sufficient investment to fully commercialise research are all challenges that must be overcome in order to accelerate further development of cell therapies. (ddw-online.com)
The regulations surrounding cell therapies must therefore be sufficiently broad to cover this wide range of therapeutic processes, while still safeguarding product safety and quality. (ddw-online.com)
From a manufacturing point of view, autologous cell therapies can be more challenging to produce than allogeneic cell therapies, as each dose is a single batch and is derived from a different source. (ddw-online.com)
ArsenalBio's work to develop multi-functional CAR-T cell therapies is enabled by Thermo Fisher's Cell Therapy Systems (CTS) portfolio of products, including the Gibco™ CTS™ Xenon™ Electroporation System and the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System. (stevenagecatalyst.com)

24h after TCR transduction, CD107a expression correlated with low expansion rates due to apoptosis of ADRB3 specific T cells in contrast to CHM1 specific transgenic T cells. (oncotarget.com)
A promising approach is provided by the transduction of CLL cells with CD40 ligand (CD40L) by viral vectors to enhance their immunogenicity. (shengsci.com)

Memory CD8 + T cell responses have the potential to mediate long-lasting protection against cancers. (lifeboat.com)
Emerging evidence indicates that Trm cells develop in human solid cancers and play a key role in controlling tumor growth. (lifeboat.com)
Dr. Blumenschein's area of focus is in new drug development, adoptive T-cell therapy and multimodality therapy for the treatment of lung and head and neck cancers. (mdanderson.org)
He is leading the Adoptive T-cell Program with the goal of developing this class of therapeutics for the treatment of Lung and Head and Neck Cancers. (mdanderson.org)
Our programmable cell therapy technology holds the potential to help patients with aggressive and complex cancers who currently have few treatment options," said Ken Drazan, M.D., co-founder and chief executive officer, ArsenalBio. (stevenagecatalyst.com)
Nevertheless, as the CART repertoire expands to other B-cell malignancies and solid cancers, we can expect to see further studies investigating potential variables regarding their function in various settings. (medpagetoday.com)
2009), it's the antigen-defined cancers vaccines that pull the interest of all researchers. (mindunwindart.com)
Particular HCC cancers vaccines derive from HCC-associated antigens, which generally consist of alpha fetoprotein (AFP), glypican 3 (GPC3), NY esophageal squamous cell carcinoma-1 (NY-ESO-1) cancers testis antigen, and individual. (mindunwindart.com)

The cells used in transplantation can either be derived from an individual patient (autologous cell therapy) or from another donor (allogeneic cell therapy). (ddw-online.com)
The American Society for Transplantation and Cellular Therapy (ASTCT) guidelines recommend a collection target of 3-5 × 10 6 CD34+ cells/kg. (medscape.com)

Subsequently, cells are transduced with CAR-encoding genes using (mostly) viral vectors. (nature.com)
Mice were followed for the growth of subsequently implanted or pre-existing tumors and survival. (jefferson.edu)

1 T cells are engineered to express CARs through viral vectors, enabling them to recognize specific target antigens. (bdbiosciences.com)

[ 4 ] Persistence of CAR T cells for as long as 3 years has been reported. (medscape.com)
The primary end point was safety and secondary end points included objective response rate, duration of response and T cell persistence. (nature.com)
At the cut-off date, available data demonstrated the long-term persistence of CAR-T cells observed in some patients for more than 100 days, and in one patient for 200 days. (pipelinereview.com)

The first report of CAR T-cell therapy was in 2010, in a patient with advanced follicular lymphoma. (medscape.com)
Yescarta), a CAR T-cell therapy for adults with large B-cell non-Hodgkin lymphoma. (ajmc.com)
Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
it was frequently categorized as diffuse small-cleaved cell lymphoma (by the International Working Formulation) or centrocytic lymphoma (by the Kiel classification). (medscape.com)

Therefore, our work highlights the therapeutic potential of vaccination-induced Trm cells to achieve potent protection against skin malignancies. (lifeboat.com)

We conducted a single-arm open-label phase 1 trial ( NCT03215810 ) of TILs administered with nivolumab in 20 patients with advanced non-small cell lung cancer following initial progression on nivolumab monotherapy. (nature.com)

This results in cross-linking of T-cells and myeloma cells and induces a potent cytotoxic T-lymphocyte response against BCMA-expressing cells. (medscape.com)

Manufacture of CAR T cells is most commonly done using retroviral vectors. (medscape.com)
In this study, we investigated the use of CD20 as safety switch after retroviral transfer to T cells with different cytomegalovirus (CMV) specificities, and conclude that CD20 may be broadly applicable as safeguard in adoptive T-cell therapy. (haematologica.org)
The retroviral vector transduced final CAR T cell product was often unstable, reaching the tumor-stromal interface, yet not moving beyond into the tumor. (urologytimes.com)

Importantly, the benefit of this platform is that it will provide immunologic memory such that the CAR T cells will persist at the site of tumor, leading to more time for the cell to elicit an antitumor response. (urologytimes.com)
We also analyze the elements that may enhance the antitumor efficiency and the basic safety parameters of constructed T cells. (mindunwindart.com)

Addeo, A., Banna, G. L., Metro, G. & Di Maio, M. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. (nature.com)

PD-L1 CAR haNKs reduced levels of macrophages and other myeloid cells endogenously expressing high PD-L1 in peripheral blood from patients with head and neck cancer. (elifesciences.org)
Neoantigen-reactive T cell clonotypes increased and persisted in peripheral blood after treatment. (nature.com)
Peripheral blood mononuclear cells (PBMC) were collected from healthy donors after approval by the LUMC institutional review board and informed consent according to the Declaration of Helsinki. (haematologica.org)
At least 6.5 x 10(8) [corrected] mononuclear cells/kg patient weight were collected from the peripheral blood of each patient, cyropreserved, and returned intravenously following CBV administration. (shengsci.com)

Here, we demonstrated that intradermal administration of clinically relevant vaccines efficiently induces Trm cells specific for tumor-specific and self-antigens that accumulate in vaccinated and non-vaccinated skin. (lifeboat.com)
Here we demonstrated that a single intradermal administration of gene- or protein-based vaccines efficiently induces specific Trm cell responses against models of tumor-specific and self-antigens, which accumulated in vaccinated and distant non-vaccinated skin. (lifeboat.com)
Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. (stanford.edu)
Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma. (cdc.gov)

These receptors have both extracellular and intracellular components. (medscape.com)
Classical " CARs consist of an extracellular binding domain mostly derived from a monoclonal antibody fragment (single-chain variable fragment-scFv), which is linked to intracellular binding domains of the T-cell receptor complex. (nature.com)
m IGV-001 and h IGV-001 were analyzed for extracellular ATP and high mobility group box 1 (HMGB1) as indicators of immunogenic cell death (ICD), along with flow cytometric analysis of viability, surface calreticulin, and reactive oxygen species. (jefferson.edu)
CAR comprises an extracellular, cancer-specific antibody fused with the intracellular signaling activation domains of CD3 and co-activation ligands, such as CD28 or 4-1BB [ 17 , 18 ], which provide engineered T cells with an MHC‐independent mechanism through which to kill cancer cells directly. (biomedcentral.com)

This important molecule promotes NKT cell survival and function within tumor tissues. (texaschildrens.org)
Secondary aims of the study will include to evaluate CAR T cell distribution with the cerebrospinal fluid (CSF), the extent to which CAR T cells egress or traffic into the peripheral circulation or blood stream, and, if tissues samples from multiple time points are available, also evaluate the degree of HER2 expression at diagnosis versus at recurrence. (fredhutch.org)
The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. (oncotarget.com)
This design, founded on the oxygen-dependent degradation domain (ODD), might be particularly useful for targeting common antigens shared between normal and neoplastic tissues. (biomedcentral.com)
Cells Tissues Organs. (cancercentrum.se)

Autoreactive B cells play a key role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. (bvsalud.org)
In this paper, we discuss the evolving strategies for targeting autoreactive B cells via CAR T cells, which might be used for targeted therapy in autoimmune diseases. (bvsalud.org)

Anatomy28

Organisms8

Diseases51

Chemicals and Drugs81

Analytical, Diagnostic and Therapeutic Techniques and Equipment51

Phenomena and Processes41

Disciplines and Occupations1

Information Science4

Health Care9

Solid tumors22

Immunotherapy22

Irradiated allogeneic1

Dendritic cells7

CD1915

Melanoma11

Vivo14

Microenvironment6

Cytotoxicity4

Lymphocytes6

Relapsed or refractory2

Cytokines5

Recognition10

Stem19

Specificity3

Multiple myeloma8

Specific T cell rece2

Refractory6

Monoclonal antibodies2

Brain tumors1

Clinical15

Adoptive transfer1

Proliferation6

Toxicity5

Preclinical4

Effector9

Human epidermal growth f1

Immunotherapies4

Vitro4

Signs of anti-tumor activity2

Efficacy1

Immunity7

Therapy with autologous1

Infusion6

Malignant cells3

Immune response2

Blockade3

Bispecific3

Therapies19

Transduction2

Cancers8

Transplantation2

Subsequently2

Target antigens1

Persistence3

Lymphoma5

Malignancies1

TILs1

BCMA1

Retroviral3

Antitumor2

Checkpoint1

Peripheral blood4

Induces4

Extracellular4

Tissues5

Autoimmune2